酰基辅酶A结合蛋白（ACBP）：自噬检查点，可作为改善癌症免疫监视的靶点。

IF 6.5 2区医学 Q1 IMMUNOLOGY

Oncoimmunology Pub Date : 2024-10-07 eCollection Date: 2024-01-01 DOI:10.1080/2162402X.2024.2413200

Léa Montégut, Isabelle Martins, Guido Kroemer

引用次数: 0

摘要

由DBI编码的酰基辅酶A结合蛋白（ACBP）是一种组织激素，可限制多种类型细胞的自噬，从而起到细胞外自噬检查点的作用。我们最近在《分子癌症》（Molecular Cancer）杂志上报道，中和 ACBP 的单克隆抗体能改善乳腺癌和肺癌的免疫监视。此外，在临床前模型中，中和 ACBP 可改善 PD-1 阻断新辅助化疗免疫疗法的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Acyl CoA binding protein (ACBP): an autophagy checkpoint that can be targeted for improving cancer immunosurveillance.

Acyl CoA binding protein (ACBP) encoded by DBI is a tissue hormone that limits autophagy in multiple cell types, hence acting as an extracellular autophagy checkpoint. We recently reported in Molecular Cancer that monoclonal antibodies neutralizing ACBP improve immunosurveillance of breast and lung carcinomas. Moreover, ACBP neutralization improves the outcome of neoadjuvant chemoimmunotherapy with PD-1 blockade in preclinical models.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoimmunology ONCOLOGYIMMUNOLOGY-IMMUNOLOGY

CiteScore

12.50

自引率

2.80%

发文量

276

审稿时长

24 weeks

期刊介绍： OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy. As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology. The journal covers a wide range of topics, including: -Basic and translational studies in immunology of both solid and hematological malignancies -Inflammation, innate and acquired immune responses against cancer -Mechanisms of cancer immunoediting and immune evasion -Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells -Immunological effects of conventional anticancer therapies.